0520 GMT January 28, 2022
In a trial, pembrolizumab kept head and neck cancers at bay for an average of two years — five times longer than under chemotherapy.
The patients also suffered far fewer side-effects, BBC reported.
Cases of head and neck cancers are rising in the UK and most are diagnosed late, when they are hard to treat.
'I can get on with my life'
Derek Kitcherside, 70, from Leicestershire, believes he wouldn't be here without pembrolizumab.
He was diagnosed with cancer of the voicebox in 2011. When he started coughing up blood three years later, after receiving standard treatment, he was told the cancer had spread to his lungs and was probably incurable.
Derek asked to go on a drug trial and traveled to London every three weeks for two years for treatment with pembrolizumab.
"My tumor was shrinking all the time and I felt a bit better every time I went," he said. "It made a huge difference to my life."
Regular scans show the disease is now stable and the tumor is still getting smaller.
"I'm very pleased I can get on with my life," Derek said.
"I don't think I'd be here without it."
What is immunotherapy?
It is a treatment that does not kill cancer cells itself but instead stimulates the body's immune system to attack them.
Pembrolizumab is already being used to treat a wide range of advanced cancers, including melanoma — a type of skin cancer that spreads easily.
Experts believe the drug has the potential to treat many more.
When is it used?
Normally, immunotherapy is used after standard treatments like chemotherapy have failed but this trial, in 882 patients from 37 countries, suggests it should be used earlier — and for some people it should be the go-to option.
The drug is given to patients regularly through a drip when their cancer has returned or spread, and is considered incurable.
Why is it better than current treatment?
It is kinder, safer and can keep patients alive for longer, the study in The Lancet found. But it may not work for everyone.
In people with advanced head and neck cancer who responded to the drug — one in four — their cancer shrank or stabilized for an average of 23 months.
By comparison, although more patients (36 percent) responded positively to standard chemotherapy treatment, the improvements lasted on average for only four and a half months.
Those with larger, more aggressive tumors were given the drug in combination with chemotherapy to help slow progress of the disease — which was kept in check for an average of seven months.
So who could benefit?
The trick is identifying people with tumors that will respond, said Prof. Kevin Harrington, consultant clinical oncologist at The Royal Marsden NHS Founation Trust, who led the study,
A test for the presence of immune marker PD-L1 in the tumor means doctors can work this out.
Harrington said approximately 85 percent of people with advanced or relapsed head and neck cancer would be eligible for pembrolizumab — around 1,300 patients a year.
Why is it kinder?
At the moment, the recommended treatment is a toxic combination of chemotherapy and antibody therapy, which often makes people feel very sick.
The extreme treatment can also cause damage to the kidneys, hands and feet.
Patients given the immunotherapy drug experienced far fewer side-effects.
"It's more sensible and less toxic — patients live longer and feel better," said Harrington.
What does this mean for patients?
"This study is very exciting", said Paul Workman, from the Institute of Cancer Research.
"Firstly because it shows that immunotherapy can have dramatic benefits for some patients with head and neck cancer when used as a first-line treatment, and secondly because the researchers have devised a test for picking out who is most likely to benefit."
He said all new drugs coming on to the market should be accompanied by a test to target their uses as precisely as possible.
In the US and the EU, pembrolizumab has been approved for use on its own and with chemotherapy for advanced head and neck cancer, but not yet in the UK.
It could be at least two years before it is approved for use on the UK’s National Health Service (MHS).